Novo Nordisk has bought a biomanufacturing facility earmarked for closure by Olympus Biotech and begun rehiring staff in order to support its haemophilia product pipeline.
GSK’s Eperzan (albiglutide) has become the first approved drug to use the Veltis half-life extension technology and, according to Novozymes, may make it a strong competitor in the GLP-1 agonist market.